NDAORALTABLET
Approved
May 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDROPRES 25 is a fixed-dose oral combination tablet containing hydrochlorothiazide (a thiazide diuretic) and reserpine (an antihypertensive alkaloid). This product treats hypertension by combining diuretic and sympatholytic mechanisms to reduce blood pressure. The combination leverages complementary pharmacology to provide additive antihypertensive effects.
LOE Approaching
This mature branded product faces significant LOE risk with minimal linked roles, indicating a small, legacy-focused commercial team preparing for generic erosion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYDROPRES 25 offers limited career development given its approaching LOE and minimal linked job openings. This role is best suited for professionals seeking experience in legacy product management, generic transition strategy, or payer relations in a declining portfolio.
Brand ManagerMedical Science Liaison
Worked on HYDROPRES 25 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.